Got $1,000? You Might Want To Buy These 2 Coronavirus Stocks Now
Dozens of companies have joined the race to develop a vaccine or a treatment for COVID-19. However, many of these companies remain risky investments.
For instance, shares of Sorrento Therapeutics (NASDAQ: SRNE) soared by more than 100% in one day after the company announced it had discovered a potential cure for COVID-19. Despite this great bit of news, Sorrento Therapeutics has only one approved product that doesn't generate much revenue, a dwindling cash balance, no pipeline candidates in late-stage trials, and a long road ahead before it can even hope to launch a COVID-19 vaccine on the market. In short, investors had better avoid this particular stock.
With that said, several companies currently involved in the fight against COVID-19 deserve serious consideration based on their core businesses. Here are two that investors with cash on the sidelines would do well to consider buying today: Merck (NYSE: MRK) and Novavax (NASDAQ: NVAX).
Source Fool.com
